Takeda Pharmaceuticals International AG Sustainability Profile
Takeda Pharmaceuticals International AG, commonly referred to as Takeda, is a leading global biopharmaceutical company headquartered in Switzerland (CH). Founded in 1781, Takeda has established a strong presence in key operational regions, including North America, Europe, and Asia, focusing on innovative medicines that address unmet medical needs. Specialising in areas such as oncology, gastroenterology, neuroscience, and rare diseases, Takeda is renowned for its commitment to research and development. The company’s core products, including therapies like Ninlaro and Entyvio, are distinguished by their efficacy and patient-centric approach. With a robust pipeline and a dedication to sustainability, Takeda has achieved notable milestones, positioning itself as a trusted leader in the pharmaceutical industry. Its emphasis on collaboration and innovation continues to drive advancements in healthcare worldwide.
DitchCarbon Score
How does Takeda Pharmaceuticals International AG's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Real Estate Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Takeda Pharmaceuticals International AG's score of 70 is higher than 83% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Takeda Pharmaceuticals International AG, headquartered in Switzerland (CH), currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Takeda Pharmaceutical Company Limited, which may influence its climate commitments and emissions reporting. As part of its climate strategy, Takeda Pharmaceuticals International AG inherits sustainability initiatives and targets from its parent company, Takeda Pharmaceutical Company Limited. This includes commitments to the Science Based Targets initiative (SBTi) and participation in the Carbon Disclosure Project (CDP). However, specific reduction targets or achievements have not been detailed in the available data. The company is also involved in various climate initiatives, although no specific pledges or commitments have been disclosed. As a subsidiary, it aligns with the broader sustainability goals set by its parent company, which may include significant reductions in greenhouse gas emissions across all scopes. In summary, while specific emissions data and reduction targets for Takeda Pharmaceuticals International AG are not available, the company is part of a larger corporate family that is actively engaged in climate commitments and sustainability efforts.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 96,000,000 | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 161,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 226,000,000 | 000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
How Carbon Intensive is Takeda Pharmaceuticals International AG's Industry?
How Carbon Intensive is Takeda Pharmaceuticals International AG's Location?
Takeda Pharmaceuticals International AG's Scope 3 Categories Breakdown
Takeda Pharmaceuticals International AG's Scope 3 emissions, which decreased by 29% last year and increased significantly since 2015, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 63% of Scope 3 emissions.
Top Scope 3 Categories
Takeda Pharmaceuticals International AG's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Takeda Pharmaceuticals International AG has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
